Retrospective study of immune response post COVID-19 vaccination in patients with multiple myeloma and related disease

Retrospective study of immune response post COVID-19 vaccination in patients with multiple myeloma and related disease - Retrospective study of immune response post COVID-19 vaccination in patients with multiple myeloma and related disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046387

Enrollment

Registered

2021-12-20

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma and related disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with plasma cell disorders whose serum anti-S antibody titer was measured after SARS-CoV-2 vaccination.

Exclusion criteria

Exclusion criteria: Patient who is considered ineligible for enrolling the study by a principal investigator or sub-investigator

Design outcomes

Primary

Measure	Time frame
correlation between serum antibody titer to SARS-COV2-S after vaccination and the length of time after vaccination	—

Countries

Japan

Contacts

Public ContactHiroshi Kosugi

Ogaki Municipal Hospital Department of Hematology

h-kosugi@umin.ac.jp0584-81-3341

Outcome results